华夏创新医药龙头混合C(012982)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
1,668,370.14 |
64,767,343.95 |
67,984,279.65 |
-26,494,020.32 |
| 利息合计 |
54,561.64 |
81,807.21 |
36,181.91 |
96,841.42 |
| 其中:存款利息收入 |
54,561.64 |
81,807.21 |
36,181.91 |
96,841.42 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-30,640,649.31 |
68,389,698.73 |
24,725,807.96 |
-21,407,795.29 |
| 其中:股票投资收益 |
-31,110,487.79 |
67,526,488.31 |
24,208,416.62 |
-22,700,593.38 |
| 基金投资收益 |
- |
- |
- |
- |
| 债券投资收益 |
- |
- |
- |
18,168.39 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
- |
- |
- |
- |
| 股利收益 |
469,838.48 |
863,210.42 |
517,391.34 |
1,274,629.70 |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
31,526,393.78 |
-4,944,622.83 |
42,905,454.96 |
-5,315,356.49 |
| 其他收入 |
728,064.03 |
1,240,460.84 |
316,834.82 |
132,290.04 |
| 费用 |
2,183,578.97 |
3,651,194.05 |
1,592,371.23 |
3,065,174.26 |
| 管理人报酬 |
1,475,867.18 |
2,459,534.29 |
1,058,764.59 |
2,021,090.20 |
| 基金托管费 |
245,977.89 |
409,922.29 |
176,460.72 |
336,848.41 |
| 销售服务费 |
380,423.32 |
629,127.45 |
282,755.30 |
559,153.00 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
81,310.58 |
152,610.02 |
74,390.62 |
148,082.45 |
| 利润总额 |
-515,208.83 |
61,116,149.90 |
66,391,908.42 |
-29,559,194.58 |
欢迎访问证券之星!请点此与我们联系 版权所有: Copyright © 1996-年